Hirschler, Ben

Follow Hirschler, Ben: Website |


Pfizer continues to fine-tune R&D spending: No ‘one-time fix’

Pfizer continues to fine-tune R&D spending: No ‘one-time fix’

October 8, 2013 7:03 am by | 0 Comments

CAMBRIDGE, England (Reuters) – Nearly three years after a cost-cutting drive that stunned many in the drugs industry, Pfizer Inc’s head of research Mikael Dolsten says his scientists are delivering more for less.
The ability of the biggest U.S. drugma…


Hefty price increase for some four-strain flu vaccines

Hefty price increase for some four-strain flu vaccines

September 19, 2013 10:32 am by | 0 Comments

LONDON (Reuters) – Big drugmakers are seeking a boost from new four-in-one influenza vaccines that will be available for the first time this flu season.
Offering more protection to patients, the new quadrivalent vaccines provide a route to premium pri…



Comments from Roche on core business call Alexion acquisition into question

Comments from Roche on core business call Alexion acquisition into question

September 11, 2013 10:21 am by | 0 Comments

LONDON (Reuters) – Treating ultra-rare diseases is a distinct business from Roche’s current area of expertise, the Swiss group’s head of pharmaceuticals said, in comments that may cast doubt on its interest in Alexion Pharmaceuticals.
“Our business is…


One pill easier to swallow than four: Study finds better drug compliance with heart polypill

One pill easier to swallow than four: Study finds better drug compliance with heart polypill

September 3, 2013 4:01 pm by | 0 Comments

AMSTERDAM (Reuters) – Doctors urging heart patients to “keep taking the tablets” would have a more success if they used a new combination medicine known as a polypill, according to research published on Tuesday.
An international trial involving 2,000 …


Cancer treatment R&D is outpacing the search for new heart drugs, doctors want research priorities rebalanced

Cancer treatment R&D is outpacing the search for new heart drugs, doctors want research priorities rebalanced

September 3, 2013 4:12 am by | 1 Comments

AMSTERDAM (Reuters) – The hunt for new heart drugs is losing momentum as resources are switched to other areas, notably cancer research, where investors get a better bang for their buck.
Cardiologists fear the fight against heart disease could stall a…


Future uncertain for Amgen, Cytokinetics heart failure drug as it misses trial goal

Future uncertain for Amgen, Cytokinetics heart failure drug as it misses trial goal

September 3, 2013 2:01 am by | 0 Comments

AMSTERDAM (Reuters) – An experimental heart failure drug from Amgen and Cytokinetics missed its goal of improving shortness of breath in a mid-stage clinical trial, leaving its future uncertain.
Despite the setback in the 613-patient trial using an in…


Mixed safety report for diabetes pills: DPP-4 therapies didn’t raise risk of heart of attack but could be linked to heart failure

Mixed safety report for diabetes pills: DPP-4 therapies didn’t raise risk of heart of attack but could be linked to heart failure

September 2, 2013 2:01 am by | 0 Comments

AMSTERDAM (Reuters) – Diabetes pills known as DPP-4 therapies got a mixed safety report on Monday as studies showed they did not raise the risk of heart attacks but might be linked to heart failure, where the heart fails to pump blood adequately.
Reas…



Researchers create surgical knife that can detect cancer tissue

Researchers create surgical knife that can detect cancer tissue

July 18, 2013 2:00 pm by | 1 Comments

LONDON (Reuters) – Scientists have created an “intelligent” surgical knife that can detect in seconds whether tissue being cut is cancerous, promising more effective and accurate surgery in future.
The device, built by researchers at London’s Imperial…


Scientist unravel how the ‘obesity gene’ makes people fat

Scientist unravel how the ‘obesity gene’ makes people fat

July 15, 2013 12:00 pm by | 0 Comments

LONDON (Reuters) – Scientists have unraveled how a gene long associated with obesity makes people fat by triggering increased hunger, opening up potential new ways to fight a growing global health problem.
A common variation in the FTO gene affects on…


Crack down on high prices and corporate malpractice cast shadow on emerging markets for big pharma

Crack down on high prices and corporate malpractice cast shadow on emerging markets for big pharma

July 12, 2013 11:15 am by | 0 Comments

LONDON/HONG KONG (Reuters) – International drugmakers are under fire in emerging markets as governments crack down on high prices and corporate malpractice, raising a risk to the price premiums global players enjoy over local rivals.
China’s probe int…


Less expensive IVF treatment designed for poorer countries

Less expensive IVF treatment designed for poorer countries

July 8, 2013 5:38 am by | 0 Comments

LONDON (Reuters) – Belgian doctors have developed a low-cost version of test-tube baby technology for use in developing countries, where sophisticated Western systems are unaffordable for most couples.
The researchers said on Monday their simplified p…


British newborn first to be screened for genetic defects with new, cheaper screening

British newborn first to be screened for genetic defects with new, cheaper screening

July 7, 2013 7:12 pm by | 0 Comments

LONDON (Reuters) – The first test-tube baby to come from an embryo screened for genetic defects using a new, low-cost technique that could improve in-vitro fertilization success rates was born last month and is a healthy boy.
The birth in June was ann…


Two men with HIV have no evidence of the infection after stem-cell therapy

Two men with HIV have no evidence of the infection after stem-cell therapy

July 3, 2013 7:53 am by | 0 Comments

LONDON (Reuters) – Two men with HIV have been off AIDS drugs for several months after receiving stem-cell transplants for cancer that appear to have cleared the virus from their bodies, researchers reported on Wednesday.
Both patients, who were treate…


Drug pricing system leads Eisai to pull its epilepsy drug from Germany

Drug pricing system leads Eisai to pull its epilepsy drug from Germany

June 25, 2013 8:42 am by | 0 Comments

LONDON (Reuters) – Japanese drugmaker Eisai is to stop selling its new epilepsy therapy Fycompa in Germany – the biggest market for the product – following a row over the price it can charge for the drug.
The case highlights the growing battle-lines b…


Investor-backed thinktank calls for changes to drug funding and approval

Investor-backed thinktank calls for changes to drug funding and approval

June 18, 2013 7:02 pm by | 0 Comments

LONDON (Reuters) – Pharmaceutical companies need to boost the benefits of drug research by working with regulators and healthcare providers to overhaul the way medicines are approved and paid for, a thinktank backed by investors says.
After years of d…